Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation

Exclusion Criteria

• •any known chronic or acute medical condition with or without the need for chronic pharmacologic therapy or any condition that may interfere with normal biodistribution of DFH-12. Includes but not limited to:
• •* lung parenchymal or lung vascular diseases such as chronic obstructive pulmonary disease,
• •* bronchitis,
• •* lung cancer,
• •* pleural effusion,
• •* emphysema,
• •* asthma,
• •* pulmonary fibrosis,
• •* occupational lung disease,
• •* pulmonary hypertension (primary or secondary),
• •* systemic hypertension,
• •* diabetes,
• •* cancer,
• •* kidney disease,
• •* liver disease,
• •* heart failure or previous myocardial infarction,
• •* coronary artery disease,
• •* peripheral vascular disease or inflammatory disease;
• •subjects requiring chronic administration of any substance for a medical condition, active smoking or history of smoking for more than one year in the past 10 years, known self-reported alcoholism (active or abstinent);
• •unable to tolerate study procedures ex.(venipuncture, movement restrictions during imaging);
• •previous nuclear study since one week (to avoid cross-contamination)